Regulus Therapeutics reported $10.52M in Current Liabilities for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Alnylam Pharmaceuticals ALNY:US USD 772.79M 115.11M
AstraZeneca AZN:LN USD 24.85B 3.04B
Astrazeneca AZN:US USD 24.85B 3.04B
Biogen BIIB:US USD 3.93B 1.09B
Celldex Therapeutics CLDX:US USD 16.29M 13.66M
Gilead Sciences GILD:US USD 10.42B 1.2B
GlaxoSmithKline GSK:LN GBP 20.95B 16.88B
Intercept Pharmaceuticals ICPT:US USD 221.58M 70.16M
Intrexon XON:US USD 104.86M 74.96M
Lexicon Pharmaceuticals LXRX:US USD 18.44M 1.58M
Ligand Pharmaceuticals LGND:US USD 135.24M 32.61M
Omeros OMER:US USD 39.51M 1.01M
Regulus Therapeutics RGLS:US USD 10.52M 4.69M
Sangamo Biosciences SGMO:US USD 122.36M 2.37M
Spectrum Pharmaceuticals SPPI:US USD 49.62M 8.58M
Takeda 4502:JP JPY 2.39T 224.78B
Vital Therapies VTL:US USD 11.51M 1.11M
YTE INCY:US USD 1.01B 79.92M